Infect Disord Drug Targets . Role of key point Mutations in Receptor Binding Domain of SARS-CoV-2 Spike Glycoprotein

[tetano]

Infect Disord Drug Targets


. 2020 Aug 4.
doi: 10.2174/1871526520666200804161650. Online ahead of print.
Role of key point Mutations in Receptor Binding Domain of SARS-CoV-2 Spike Glycoprotein


Bipin Singh ¹



Affiliations

• PMID: 32753027
• DOI: 10.2174/1871526520666200804161650

Abstract

The recent outbreak of novel coronavirus (SARS-CoV-2 or 2019-nCoV) and its worldwide spread is posing one of the major threats to human health and the world economy. It has been suggested that SARS-CoV-2 is similar to SARSCoV based on the comparison of the genome sequence. Despite the genomic similarity between SARS-CoV-2 and SARSCoV, the spike glycoprotein and receptor binding domain in SARS-CoV-2 shows the considerable difference compared to SARS-CoV, due to the presence of several point mutations. The analysis of receptor binding domain (RBD) from recently published 3D structures of spike glycoprotein of SARS-CoV-2 (Yan, R., et al. (2020); Wrapp, D., et al. (2020); Walls, A. C., et al. (2020)) highlights the contribution of a few key point mutations in RBD of spike glycoprotein and molecular basis of its efficient binding with human angiotensin-converting enzyme 2 (ACE2).

Keywords: 2019-nCoV; ACE2; COVID-19; Coronavirus; Pandemic; Spike protein.